DT-PACE

DT-PACE is a chemotherapy regimen that is used in the treatment of multiple myeloma, a type of blood cancer. The regimen includes the drugs dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide.

Overview

DT-PACE is a high-dose chemotherapy regimen that is often used as a salvage therapy for patients with relapsed or refractory multiple myeloma. The regimen includes six drugs: dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide. These drugs work together to kill cancer cells and slow the growth of new cancer cells.

Treatment

The DT-PACE regimen is typically administered in a hospital setting due to the high doses of chemotherapy involved. Patients receive the drugs through a vein over several days. The exact schedule and dosage of the drugs may vary depending on the patient's overall health and the specifics of their cancer.

Side Effects

Like all chemotherapy regimens, DT-PACE can cause side effects. These may include nausea, vomiting, loss of appetite, fatigue, and hair loss. More serious side effects can include low blood cell counts, which can increase the risk of infection, bleeding, and anemia. Patients may also experience nerve damage, which can cause numbness or tingling in the hands and feet.

Efficacy

Several studies have shown that DT-PACE can be effective in treating multiple myeloma, particularly in patients who have not responded to other treatments. However, the regimen is also associated with a high rate of side effects, which can make it difficult for some patients to tolerate.

See Also

• Chemotherapy
• Multiple Myeloma
• Dexamethasone
• Thalidomide
• Cisplatin
• Doxorubicin
• Cyclophosphamide
• Etoposide

DT-PACE Resources
Latest articles Most recent articles Ongoing trials	Wikipedia